Compare IPDN & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPDN | APRE |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5M | 10.6M |
| IPO Year | 2012 | 2019 |
| Metric | IPDN | APRE |
|---|---|---|
| Price | $0.82 | $0.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.10 |
| AVG Volume (30 Days) | 74.0K | ★ 304.2K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.22 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,054,219.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.68 | $0.55 |
| 52 Week High | $12.39 | $2.22 |
| Indicator | IPDN | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 40.02 | 50.36 |
| Support Level | N/A | $0.57 |
| Resistance Level | $1.02 | $0.98 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 41.35 | 21.03 |
Professional Diversity Network Inc provides access to networking, training, educational, and employment services to its registered users. It has three operating segments: the TalentAlly Network segment, which maintains and operates job board software and hosts career fairs; the National Association of Professional Women (NAPW) segment, which is a women-only professional networking organization; the RemoteMore segment; and Corporate Overhead. The company generates the majority of its revenue from the TalentAlly Network Segment.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.